west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "迷走神经刺激术" 7 results
  • 迷走神经刺激治疗难治性癫痫:欧洲347例儿童24个月随访研究

    为了进一步探究迷走神经刺激术(Vagus nerve stimulation, VNS)在儿童难治性癫痫中的作用, 进行了连续随访达24个月, 系迄今最大样本量的多中心回顾性研究。主要目标是评估VNS术后癫痫主要发作类型(定义为最易致残的发作类型)的频率变化, 连续收集从基线开始一直到植入术后6、12及24个月的患者数据。统计人群包括347例患者(年龄6个月~17.9岁)。在植入后第6、12及24月, 分别有32.5%、37.6%及43.8%的患者主要发作类型的发作与基线相比, 有50%减少。亚组分析中, 在试验期间没有更换抗癫痫药物(AEDs)的患者有更好的反应。较好的结果也存在于所有次要指标, 包括癫痫发作持续时间、严重程度和发作后严重程度、生活质量、安全性等。多组分析表明VNS每天总放电量与反应效率有相关性。VNS治疗被认为是局灶性结构性癫痫患儿的附加治疗, 指那些经过两种及以上AEDs治疗后仍不适合外科手术的患者。全面性发作, 有遗传及结构异常的, 如Dravet综合征和Lennox-Gastaut综合征的患者能从VNS治疗中获益。结果表明随访24个月后, 难治性癫痫患儿通过附加的VNS治疗能够减少癫痫发作频率, 安全性良好; 多组分析表明VNS有剂量相关性。

    Release date:2016-10-02 06:51 Export PDF Favorites Scan
  • 迷走神经刺激术治疗药物难治性癫痫中影响治疗效果的相关因素分析

    迷走神经刺激术(Vagus nerve stimulation,VNS)自 1997 年经美国食品药品监督局批准以来,应用越来越广泛,目前为止,全世界约有 80 000 多例药物难治性癫痫患者接受了 VNS 治疗。大量文献证实,VNS 不仅能减少药物难治性癫痫患者的发作频率,还能减轻癫痫发作严重程度、缩短发作的持续时间或发作后的恢复时间,改善患者生活质量。尽管如此,仍有一部分药物难治性癫痫患者 VNS 治疗效果不理想,甚至无效。为此,选择适合 VNS 治疗的患者,术前根据相关影响因素预测治疗效果尤为重要。文章以综述形式阐述可能影响 VNS 治疗癫痫效果的因素。

    Release date:2018-05-22 02:14 Export PDF Favorites Scan
  • 迷走神经刺激术治疗儿童难治性癫痫的研究进展

    自 1997 年美国食物药物管理局批准迷走神经刺激术(Vagus nerve stimulation,VNS)作为≥12 岁难治局灶性癫痫患者的辅助治疗以来,VNS 因其有效性、相对安全性被广泛应用。但大部分研究主要针对成年药物难治性癫痫(Drug refractory epilepsy,DRE)患者,儿童是 DRE 的高发人群,癫痫发作对患儿生长发育、社会适应甚至家庭情况等有很大影响,随着 VNS 治疗 DRE 患儿的研究不断增多,已有研究证实 VNS 能有效控制患儿癫痫发作。为了解近年来 VNS 治疗 DRE 患儿的进展,现主要从 VNS 控制 DRE 患儿的发作机制、手术方式、术后评估等方面进行综述。

    Release date:2019-11-14 10:46 Export PDF Favorites Scan
  • 迷走神经刺激术治疗儿童药物难治性癫痫的研究进展

    癫痫患儿中约有 30% 为药物难治性癫痫,迷走神经刺激术(Vagus nerve stimulation,VNS)是药物难治性癫痫患儿无手术治疗指征时的一个选择。VNS 治疗癫痫的具体机制尚不明确,但长期大量的临床应用已证实其有效性和安全性,尤其是癫痫综合征,如 Lennox-Gastaut 综合征、Dravet 综合征,或难治性局灶性、多灶性癫痫均是很好的适应证。同时,临床应用 VNS 治疗难治性癫痫发现其对患儿的认知功能等方面亦有明显改善。文章从 VNS 治疗儿童药物难治性癫痫的发展史、参数设置、适应证、可能机制、临床应用,以及局限性和未来发展等方面进行综述,以期为相关临床应用提供一定参考。

    Release date:2020-01-09 08:49 Export PDF Favorites Scan
  • 迷走神经刺激术治疗儿童难治性癫痫的研究进展

    癫痫是一种严重威胁人类身心健康的慢性功能性神经疾病,是几个世纪以来困扰医学界的难题之一。药物难治性癫痫以反复癫痫发作为主要特征,通常规范使用 2 种及以上抗癫痫药物(AEDs)症状难以控制,伴有认知功能损害的疾病。迷走神经刺激术(Vagus nerve stimulation,VNS)是一种无需开颅、通过神经调控治疗难治性癫痫的方法,在不损害重要神经功能的前提下,通过手术的方式阻断癫痫发作时电流传导通路,从而减少或者控制癫痫发作,可以降低因痫性放电继发脑损害,进而减少抗癫痫药物使用产生的副作用。自 1997 年美国食品药品监督局批准 VNS 上市应用于治疗癫痫以来,其适应证已经从成人逐步扩展到了儿童。儿童作为癫痫患者的特殊群体,处于生长发育关键期,有效、及时的调控干预可以为患儿中枢神经系统发育创造时机,为难治性癫痫患者治疗提供新思路。文章探讨了 VNS 的年龄适应证以及在不同年龄段儿童中的应用,并对 VNS 在改善儿童认知行为,儿童遗传性癫痫、发育性和癫痫性脑病、儿童结构性病因相关性癫痫治疗的有效性,VNS 使用的安全性和不良反应等方面作一综述。

    Release date:2021-02-27 02:57 Export PDF Favorites Scan
  • The preliminary analysis of clinical effect of vagus nerve stimulation in the treatment of refractory epilepsy in children

    ObjectiveTo investigate the efficacy of vagus nerve stimulation (VNS) in the treatment of refractory epilepsy in children and the key factors affecting its efficacy. MethodsThe clinical data of 22 children with drug-resistant epilepsy who received VNS treatment in the Second People's Hospital of Hunan Province from January 2016 to April 2023 were analyzed. The average seizure reduction rate, effective rate and McHugh grade were used to evaluate the efficacy of VNS after at least 1 year follow-up. Patients with an attack reduction rate of ≥50% were defined as respondents, and Mann-Witney U test and χ2 test were used, respectively, to conduct univariate and multifactor Logistics regression analysis with statistically significant indicators (P<0.05). ResultsAmong the 22 patients, the average attack reduction rate was 12.66% at 1 month, 26.10% at 3 months, 37.47% at 6 months, 48.18% at 9 months and 54.38% at 12 months. The effective rate was 5.00%, 9.00%, 36.00%, 50.00% and 68.00%, respectively. 12 months after operation, there were 3 cases of grade I, 12 cases of grade II, 7 cases of grade III, and 0 cases of grade V. Unifactorial and multivariate Logistic regression analysis showed that the curative effect of epilepsy in children was related to the seizure type, among which the curative effect of general seizure was better than that of focal seizure (OR=0.062, P=0.014), and the curative effect of myoclonic seizure and tonic seizure was better than that of other types in general seizure. ConclusionThe clinical effect of VNS in the treatment of refractory epilepsy in children is time cumulative, and the surgical effect of myoclonic seizures and tonic seizures in general seizures is better.

    Release date: Export PDF Favorites Scan
  • Efficacy and predictive factors analysis of vagus nerve stimulation in patients with refractory MRI-negative epilepsy

    ObjectiveTo investigate the efficacy of vagus nerve stimulation (VNS) in patients with refractory magnetic resonance imaging (MRI)-negative epilepsy and to evaluate potential clinical predictors. MethodsA retrospective collection of efficacy data was conducted on 24 patients with intractable MRI-negative epilepsy treated with VNS, who were followed up for more than six months, at Beijing Tiantan Hospital and Beijing Fengtai Hospital from January 2016 to September 2023. Patients were divided into two subgroups based on their response to VNS: responders (≥50% reduction in seizure frequency) and non-responders (<50% reduction in seizure frequency). The relationship between preoperative clinical data and VNS efficacy was further analyzed to identify potential predictors of VNS efficacy. ResultsA total of 24 patients were included, with an average age of (14.26±8.39) years old. Seizure frequency was reduced by more than 50% in 37.5% of patients, and 8.3% of patients achieved seizure-free after VNS treatment. Preoperative seizure frequency and interictal epileptiform discharge type were significantly associated with VNS efficacy (P<0.05). Multivariate regression analysis showed that a monthly seizure frequency of less than 100 and focal interictal epileptiform discharges were independent predictors of VNS efficacy (P<0.05). ConclusionVNS is an effective treatment for patients with refractory MRI-negative epilepsy. Lower monthly seizure frequency and focal interictal epileptiform discharges are potential predictors of VNS efficacy. These findings provide important references for clinicians in selecting and evaluating patients for VNS treatment.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content